Avidity Biosciences (RNAM)

Executive Summary

Avidity Biosciences is a clinical-stage biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs) to deliver RNA therapeutics to muscle tissues. With a market cap of ~$11B, the company is advancing a differentiated pipeline targeting rare muscle diseases, led by three key programs: AOC 1001 (del-desiran) for myotonic dystrophy type 1 (DM1) in Phase 3, AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD) in Phase 3, and AOC 1044 for Duchenne muscular dystrophy (DMD) exon 44 skipping in Phase 2. The platform leverages antibody-mediated delivery to achieve targeted uptake and potent gene silencing, with initial clinical data demonstrating biomarker reductions and functional improvements. Avidity's late-stage trials position it as a potential first-in-class therapy for multiple neuromuscular disorders, and the company is well-capitalized to execute its clinical development plan through key readouts in 2026-2027.

Upcoming Catalysts (preview)

• H2 2026Topline data from Phase 3 HARBOR trial of AOC 1001 in DM165% success
• 2026Phase 2 data from FORTITUDE trial of AOC 1020 in FSHD60% success
• 2026Phase 2 data from EXPLORE44 trial of AOC 1044 in DMD exon 4455% success